How would you manage axial spondyloarthritis in a patient who was doing well on TNF inhibitor therapy then developed a new solid organ malignancy while on treatment?

Community
Company
News
Contact Us
Sign in

Topics: Rheumatology • Spondyloarthritis

How does the management differ if the cancer is resectable or requires systemic treatment?

Related Questions

In a patient with active spondylarthritis and uveitis who cannot take TNF inhibitors, what is your next agent of choice?

Do you start methotrexate to prevent anti-drug antibody development when using TNF inhibitors for the treatment of axial spondyloarthritis?

In patients undergoing MRI evaluation for inflammatory back pain, how long do you recommend they hold NSAIDs prior to imaging?

What is your approach to the evaluation of a patient with persistent costochondritis?

How would you approach the management of HLA-B27-associated recurrent uveitis and inflammatory back pain with a recent history of melanoma?

How would you manage a patient with highly active ankylosing spondylitis, iritis and Crohn’s, controlled with weekly adalimumab with co-morbid IgG4RD and intolerance of azathioprine due to elevated LFTs?

Do you consider it safe to continue adalimumab for spondyloarthritis in a patient who develops localized melanoma if the adalimumab has worked well?

Which biologics are you comfortable combining with vedolizumab for spondyloarthritis or psoriatic arthritis patients in the setting of well-controlled inflammatory bowel disease?

In a patient with a Factor V Leiden heterozygous mutation but no prior thrombosis, would you consider using a JAK inhibitor for the treatment of spondyloarthritis or rheumatoid arthritis if other options have been ineffective?

How would you approach a patient with axial spondyloarthritis who develops new-onset proteinuria?